Major Shareholder Reduces Stake in Rapid Micro Biosystems Ahead of Earnings

Rapid Micro Biosystems US75340L1044

A significant institutional investor has substantially decreased its holdings in Rapid Micro Biosystems in recent transactions. This divestment activity coincides with the company's final preparations to release its audited financial results for the full year 2025.

Despite the selling pressure from a key investor, recent business updates from Rapid Micro Biosystems indicate solid operational momentum. The company's preliminary figures, released on January 13, highlighted continued strong demand for its flagship "Growth Direct" platform. This system automates microbiological quality control testing within pharmaceutical manufacturing.

For the full 2025 fiscal year, preliminary revenue reached approximately $33.6 million, representing a 20% increase over the prior year. A cornerstone of the business model is its recurring revenue stream, which grew about 15% to $17.8 million. The company also secured a multi-system order from a top-20 global biopharmaceutical customer. Globally, a total of 190 Growth Direct systems are now in use.

Details of the Institutional Sales

Recent filings with the U.S. Securities and Exchange Commission (SEC) reveal the scale of the divestment by Longitude Capital Partners II. Previously holding over 10% of the company's shares, the investor sold a notable block of stock in early February.

The most recent transaction occurred on February 4, with 49,000 shares sold at an average price of $3.88. This followed earlier sales of 27,500 shares at $4.25 on February 2, and a disposal of 46,000 shares at $4.54 on January 30. In total, the investor sold over 120,000 shares in this series of transactions beginning in late January.

Market Awaits Final Audited Results

Investor attention is now firmly set on the upcoming publication of the complete, audited financial statements, expected on February 27. The preliminary data for the fourth quarter showed a 37% revenue growth to $11.3 million.

The final report is anticipated to provide crucial details on profitability metrics and cash management strategies that were not included in the preliminary announcement. Key areas of focus will be the financial impact of the company's global distribution partnership with MilliporeSigma and the progress made in improving gross margins. These factors will be critical in assessing whether the current operational growth can sustainably lead the company toward profitability.